Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 667-677

  Zhang, Jingru ^a   Ye, Jingjing ^a   Ma, Daoxin ^a   Liu, Na ^a   Wu, Hao ^a   Yu, Shuang ^a   Sun, Xiulian ^a   Tse, William ^b   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DELTA LIKE LIGAND 4; MATRIX METALLOPROTEINASE; MESSENGER RNA; NOTCH RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DNA TRANSFECTION; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84874771894     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs386     Document Type: Article

References (49)

1. Ayala, F. et al. (2009) Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia, 23, 2233-2241.
2. Hatfield, K. et al. (2006) Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer, 119, 2313-2321.
3. Padró, T. et al. (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 95, 2637-2644.
4. Hussong, J.W. et al. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 95, 309-313.
5. Hatfield, K.J. et al. (2011) Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology, 16, 351-356.
6. Kümpers, P. et al. (2008) Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood, 112, 2139-2148.
7. Madlambayan, G.J. et al. (2010) Leukemia regression by vascular disruption and antiangiogenic therapy. Blood, 116, 1539-1547.
8. Trujillo, A. et al. (2012) Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J. Oncol., 2012, 128608.
9. Payne, S.J. et al. (2011) Influence of the tumor microenvironment on angiogenesis. Future Oncol., 7, 395-408.
10. Hatfield, K. et al. (2009) Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br. J. Haematol., 144, 53-68.
11. Reikvam, H. et al. (2010) Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur. J. Haematol., 84, 239-251.
12. Wegiel, B. et al. (2009) The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia, 23, 251-261.
13. Peterson, J.E. et al. (2012) VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis, 15, 265-273.
14. Rodrigues, P. et al. (2012) The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res. Treat., 133, 769-778.
15. Palazzo, A. et al. (2010) Past, present and future of targeted therapy in solid tumors. Curr. Cancer Drug Targets, 10, 433-461.
16. Teicher, B.A. (2011) Antiangiogenic agents and targets: A perspective. Biochem. Pharmacol., 81, 6-12.
17. Li, J.L. et al. (2011) DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res., 71, 6073-6083.
18. Demarest, R.M. et al. (2011) Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood, 117, 2901-2909.
19. Li, J.L. et al. (2005) Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell, 8, 1-3.
20. Phng, L.K. et al. (2009) Angiogenesis: a team effort coordinated by notch. Dev. Cell, 16, 196-208.
21. Gale, N.W. et al. (2004) Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. U.S.A., 101, 15949-15954.
22. Ehebauer, M. et al. (2006) Notch, a universal arbiter of cell fate decisions. Science, 314, 1414-1415.
23. Scehnet, J.S. et al. (2007) Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood, 109, 4753-4760.
24. Hainaud, P. et al. (2006) The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res., 66, 8501-8510.
25. Patel, N.S. et al. (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res., 12, 4836-4844.
26. Patel, N.S. et al. (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res., 65, 8690-8697.
27. Noguera-Troise, I. et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 444, 1032-1037.
28. Li, J.L. et al. (2009) Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front. Biosci., 14, 3094-3110.
29. Thurston, G. et al. (2008) VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br. J. Cancer, 99, 1204-1209.
30. Ridgway, J. et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature, 444, 1083-1087.
31. Lobov, I.B. et al. (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. U.S.A., 104, 3219-3224.
32. Li, J.L. et al. (2007) Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res., 67, 11244-11253.
33. Siekmann, A.F. et al. (2008) Modulation of VEGF signalling output by the Notch pathway. Bioessays, 30, 303-313.
34. Suchting, S. et al. (2007) The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl Acad. Sci. U.S.A., 104, 3225-3230.
35. Funahashi, Y. et al. (2011) Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity. Vasc. Cell, 3, 2.
36. Wang, J. et al. (2011) Notch1 is involved in migration and invasion of human breast cancer cells. Oncol. Rep., 26, 1295-1303.
37. Wang, Z. et al. (2006) Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res., 66, 2778-2784.
38. Garg, P. et al. (2011) Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice. Gastroenterology, 141, 1381-1392.
39. Marin, V. et al. (2001) Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells. J. Immunol. Methods, 254, 183-190.
40. Hou, H.A. et al. (2008) Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk. Res., 32, 904-912.
41. Maffei, R. et al. (2010) Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk. Res., 34, 312-321.
42. Dincaslan, H.U. et al. (2010) Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients? Pediatr. Hematol. Oncol., 27, 503-516.
43. Faderl, S. et al. (2005) Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood, 106, 4303-4307.
44. Chen, P.M. et al. (2008) Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia. Int. J. Oncol., 32, 1335-1341.
45. Fu, L. et al. (2009) Transition of cleaved Notch1 and gene expression changes in myeloblastic leukemia cells stimulated with notch ligands. Anticancer Res., 29, 3967-3970.
46. Li, G.H. et al. (2010) Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein. Mol. Cell. Biochem., 340, 7-14.
47. Williams, C.K. et al. (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, 107, 931-939.
48. Harrington, L.S. et al. (2008) Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc. Res., 75, 144-154.
49. Holderfield, M.T. et al. (2006) HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes. Biochem. Biophys. Res. Commun., 346, 637-648.